Abstract. Twenty-eight hyperandrogenemic women suffering from infertility owing to chronic anovulation were treated with hMG. Only 7 patients exhibited the typical polycystic ovarian appearance of multiple subcortical cysts, however, a wide range (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) 
suffering from infertility owing to chronic anovulation were treated with hMG. Only 7 patients exhibited the typical polycystic ovarian appearance of multiple subcortical cysts, however, a wide range (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) cm 3) of ovarian volume was observed. The LH/FSH ratio was consistently lower than 2.5 and circulating androgens of both ovarian and adrenal origin were elevated. The 4 days dexamethasone suppression test showed more than 80% suppression of dehydroepiandrosterone-sulphate and a variable (40-60%) reduction of testosterone and androstenedione levels. Two different patterns of follicular development were observed in response to hMG. Sixteen patients ex- hibited polycystic ovarian reaction, whereas 12 women had a follicular growth pattern similar to that seen in hMG-stimulated normo-ovulatory subjects. Patients with polycystic ovarian reaction showed a significantly increased androstenedione response to hMG when compared with the other group. Moreover, the non-stimulated ovarian volume was found to be markedly greater than in subjects without polycystic reaction. Thus, ovarian stimulation of patients with mixed hyperandrogenemia may elucidate the presence of borderline polycystic ovaries; furthermore the increased accumulation of androstenedione may suggest an inherent ovarian failure.
Chronic anovulation is frequently associated with hyperandrogenemia of various origin (1) . Polycys¬ tic ovarian syndrome (PCOS) is recognized as the commonest cause of anovulation, though the exact pathomechanism of the disorder is still not clearly defined (2) . Elevated ovarian androgens arise from the tonic, LH-dependent stimulation of the thecal and stromal tissue (3, 4) , producing an unfavourable intrafollicular accumulation of testosterone (T) and androstenedione (5) . This mechanism does not explain the androgen increase in PCOS with normal immunoreactive LH level (6, 7) . In these cases either the raised LH bioactivity (8) or local, non-steroidal factors (9) may be responsible for the defect of normal follicular development.
The characteristic sonographic picture in PCOS (10) and the frequently elevated LH/FSH ratio are of great importance, but in borderline cases the diagnosis cannot be set up at the first instance. Subcapsular small cysts may shrink owing to long-last¬ ing amenorrhoea, furthermore they are not so manifest in ovarian hyperthecosis, a subgroup of ovarian hyperandrogenemia (11) .
Mixed hyperandrogenemia has been reported in 30-40% of all patients with androgen overproduc¬ tion, secreting increased amounts of T, androste¬ nedione and dehydroepiandrosterone-sulphate (DHEA-S) (12, 13) . The dexamethasone suppres¬ sion test is widely used to differentiate the adrenal from the ovarian source, usually achieving a rapid reduction (over 80%) of DHEA-S in non-tumourous adrenal hyperfunction (14) . The androgens T and androstenedione are secreted by the adrenals and ovaries in about equal amounts (15) , approx¬ imately 50% of T is produced by peripheral con¬ version of androstenedione (16) Concerning the ovarian response to ovulation in¬ duction, neither basal, nor peak E2 levels showed a significant difference between Group A and B. shows that more than 80% of the DHEA-S secre¬ tion could be abruptly eliminated in 4 days (Table  3) . However, regarding the androgens of mixed origin (T and androstenedione), only a variable (40-60%) suppression could be achieved. Statistical difference was detected only for an¬ drostenedione; both the peak level and the incre- (11) . A near normal LH/FSH ratio was found in ovarian hyperthecosis (7, 18) and the disorder was recently brought into connection with insulin resistance (9, 19 
